Eli Lilly oral weight-loss drug

Eli Lilly will seek regulatory approval to market its oral weight-loss medication, Foundayo, as a treatment for obstructive sleep apnea by the end of 2026. The decision follows a late-stage clinical trial demonstrating that the daily pill significantly reduced breathing interruptions in adults with the sleep disorder.[1][5]

The Phase 3 ATTAIN-OSA trial evaluated the drug, known generically as orforglipron, over a 52-week period. Researchers found that the medication cut sleep apnea events by nearly half for patients who were not using traditional positive airway pressure machines.[4][5]

The findings were presented at the American Heart Association Scientific Sessions in Chicago and simultaneously published in the Journal of the American Medical Association. The data establishes Foundayo as a potential alternative to both cumbersome breathing machines and injectable GLP-1 medications.[1][3]

The ATTAIN-OSA Trial Results

The global clinical program divided participants into two distinct cohorts based on their current sleep apnea treatments. One group consisted of adults who were unwilling or unable to use continuous positive airway pressure therapy, while the second group included patients already using the machines.[1][4]

For participants not using airway pressure therapy, Foundayo reduced breathing interruptions by 43.8 percent. This translated to an average of 21.1 fewer apnea events per hour of sleep, compared to a reduction of just 6.3 percent, or roughly five events, for those taking a placebo.[1][5]

Patients who continued using their CPAP machines also experienced substantial benefits from the daily pill. In this cohort, Foundayo reduced breathing interruptions by 27.5 percent, significantly outpacing the 3.0 percent reduction observed in the placebo group over the same 52-week period.[1][2]

The trial specifically targeted adults diagnosed with moderate-to-severe obstructive sleep apnea who also had obesity or overweight. Sleep apnea severity is measured by the apnea-hypopnea index, which tracks the number of times a patient's breathing partially or completely stops per hour.[4][5]

"If approved, it would be one of the first oral therapies for sleep apnea," said Dr. Vaishnavi Kundel, an associate professor of medicine at the Icahn School of Medicine at Mount Sinai. She presented the landmark findings to cardiovascular specialists in Chicago.[1]

Cardiovascular and Oxygen Benefits

Beyond reducing the frequency of breathing interruptions, the medication substantially improved how much oxygen patients retained during sleep. Foundayo reduced the sleep apnea-specific hypoxic burden—a measure of the severity and duration of oxygen drops—by 55.9 percent in the non-CPAP group.[1][4]

For patients using CPAP machines, the hypoxic burden fell by 45.8 percent. Repeated oxygen deprivation during sleep is a primary driver of the cardiovascular complications associated with sleep apnea, including hypertension, heart failure, and an increased risk of stroke.[4][5]

The trial also tracked secondary cardiovascular markers, revealing broad metabolic improvements across the patient population. Participants taking the oral medication experienced significant reductions in systolic blood pressure and high-sensitivity C-reactive protein, a key blood marker for systemic inflammation.[1][2]

These cardiovascular improvements align with the broader benefits observed in the GLP-1 drug class. By addressing both the mechanical airway blockages and the underlying systemic inflammation, the medication offers a dual approach to mitigating the long-term health risks of sleep apnea.[1][3]

"Obstructive sleep apnea is one of the most serious complications of obesity and is closely linked to cardiovascular disease," noted a senior executive from Lilly's cardiometabolic health division. The executive emphasized the critical importance of addressing both conditions simultaneously.[4]

AI

The Oral Medication Advantage

Foundayo received initial approval from the U.S. Food and Drug Administration in April 2026 for chronic weight management. Unlike earlier GLP-1 receptor agonists such as Wegovy and Zepbound, which require weekly injections, Foundayo is a small-molecule, non-peptide drug taken as a daily tablet.[1][3]

The pill format removes a significant barrier to treatment for patients who are averse to needles. Furthermore, Foundayo does not require the strict fasting or water restrictions associated with other oral GLP-1 medications, allowing patients to take it at any time of day.[3][5]

This convenience could dramatically expand access to sleep apnea treatment. Millions of diagnosed patients struggle to tolerate CPAP machines, often abandoning the therapy due to discomfort, claustrophobia, or noise, leaving their condition effectively unmanaged and their cardiovascular health at risk.[1][4]

While Eli Lilly's injectable medication Zepbound was approved for sleep apnea earlier in the year, the introduction of a highly effective pill provides a less invasive pharmacological option. The clinical data suggests the pill's efficacy rivals that of its injectable counterparts.[2][3]

The medication works by mimicking the naturally occurring GLP-1 hormone, which regulates appetite and slows gastric emptying. This mechanism helps patients feel fuller longer, leading to the substantial weight loss that ultimately relieves physical pressure on the airway.[1][5]

Weight Loss and Airway Mechanics

The improvements in sleep apnea severity were closely tied to the significant weight loss participants achieved. Over the 52-week trial, patients taking Foundayo lost an average of approximately 28 pounds, representing more than 11 percent of their initial body weight.[1][2]

In contrast, participants in the placebo groups lost only 1 to 2 percent of their body weight. The reduction in overall body mass, particularly around the neck and abdomen, directly alters the physical dynamics that cause the airway to collapse during sleep.[2][4]

Researchers noted that weight loss improves sleep apnea through multiple distinct mechanisms. These include better pharyngeal mechanics, reduced airway collapsibility, and increased lung capacity associated with the reduction of abdominal fat pressing against the diaphragm.[1][5]

However, scientists are also investigating whether GLP-1 medications exert independent effects on respiratory control centers in the brain. While weight loss is the primary driver of the observed improvements, the rapid reduction in inflammation may also play a direct role in airway muscle function.[1][3]

The dual impact of shedding obstructive fat and reducing systemic inflammation makes the GLP-1 class uniquely suited to treating sleep apnea in overweight populations. This shifts the treatment paradigm from simple symptom management to actively addressing the condition's root cause.[3][4]

Safety Profile and Next Steps

The safety profile of Foundayo in the ATTAIN-OSA trial was consistent with previous studies of the medication. The most frequently reported adverse events were gastrointestinal issues, including nausea, diarrhea, constipation, and vomiting, which are common across the GLP-1 drug class.[1][4]

These side effects were generally mild to moderate and occurred most often during the initial dose-escalation phase. However, treatment discontinuation due to adverse events was higher among participants taking Foundayo compared to those receiving the placebo.[4][5]

To mitigate these gastrointestinal effects, the medication is prescribed with a gradual dose-escalation schedule. Patients start on a low dose that is slowly increased over several weeks, allowing the digestive system to adapt to the delayed gastric emptying.[1][5]

AI

Eli Lilly confirmed it will submit the ATTAIN-OSA data to the FDA before the end of 2026. If the agency grants the expanded indication, Foundayo would become the first oral weight-loss medication explicitly approved to treat obstructive sleep apnea.[1][5]

The approval would mark another major expansion for the GLP-1 market. It moves the drugs further beyond diabetes and obesity management into the treatment of complex, overlapping cardiometabolic conditions that affect tens of millions of adults globally.[2][3]